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effectiveness of new medicines are increasingly being used to inform
decisions on their reimbursement. Assessments of added clinical
beneﬁt are invariably based on evidence generated to support
registration. Objective: Our objective was to identify and characterize
signiﬁcant problems relating to the quality of the clinical evidence in
submissions to the Australian Pharmaceutical Beneﬁts Advisory
Committee (PBAC) seeking subsidy on the Pharmaceutical Beneﬁts
Scheme and thus determine whether the evidence presented to the
committee was “ﬁt for purpose.” Methods: We conducted a retro-
spective analysis of submissions considered by the PBAC between
2005 and 2012 using a published evaluation framework. We devel-
oped an additional framework to categorize signiﬁcant problems in
more detail. Signiﬁcant problems related to the choice of compara-
tor, the unavailability of randomized clinical trial evidence, poor-
quality data, a claim of clinical superiority, and a claim of clinicalee front matter Copyright & 2015, International S
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ndence to: Michael Wonder, PO Box 470, Cronulla,noninferiority. Results: We identiﬁed 261 signiﬁcant problems in 479
major submissions. There was a signiﬁcant problem with the
sponsor’s choice of comparator in 11% of the submissions. The most
common signiﬁcant problem (29%) was the determination of a
medicine’s comparative performance in the target patient popula-
tion. Conclusions: The supporting clinical evidence is the founda-
tion of a PBAC submission. We found a poor ﬁt for purpose; on
average, one in every two major submissions had a signiﬁcant
problem with the supporting evidence. The ﬁndings from our study,
if conﬁrmed in other jurisdictions, raise important questions regard-
ing what clinical evidence should be generated to support the
reimbursement of new medicines.
Keywords: decision making, evidence, quality, reimbursement.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Governments of the developed world currently face challenges in
ensuring that their constituents are able to access new and effective
health care technologies in a timely and affordable manner. They
have promoted the use of health technology assessment (HTA) to
facilitate efﬁcient use of their limited public resources. Although
some undertake assessments of comparative economic effectiveness
(“value for money”), a common denominator for all is an assessment
of comparative clinical effectiveness (“level of added clinical beneﬁt”)
[1]. Assessments of added clinical beneﬁt, be they single or multiple
and direct or indirect, are invariably based on evidence generated to
support registration. Few have studied whether the clinical evidence
generated to support the registration of newmedicines is well suited
for reimbursement/coverage decision making. Insofar as access to
new medicines is becoming increasingly dependent on reimburse-
ment, this is an important public health issue.Australia has considerable experience in the use of HTA to
inform reimbursement decision making. The Pharmaceutical
Beneﬁts Scheme (PBS) was established in 1953 under the National
Health Act to guarantee Australians subsidized access to essen-
tial medicines. The National Health Act also established the
Pharmaceutical Beneﬁts Advisory Committee (PBAC) to make
recommendations to the Commonwealth Minister for Health
regarding the subsidy of medicines on the PBS. The PBAC has
20 years experience in assessing submissions to list new medi-
cines on the PBS or make a substantial change to currently listed
medicines (so-called major submissions) in terms of their com-
parative clinical and economic effectiveness [2].
The main objective of our study was to identity and then
characterize signiﬁcant problems relating to the quality of the
clinical evidence in major submissions to the PBAC using the
evaluation framework of Hill et al. [3] with information on the
submissions from their public summary documents (PSDs) [4].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
necessarily reﬂect the views or practices of our previous and/or
NSW, Australia 2230.
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on PBAC’s decision making and thus determine whether the
clinical evidence presented to the committee was “ﬁt for
purpose.”Methods
Because the focus of our study was the quality of the clinical
evidence, aspects not directly related to this (i.e., modeling
issues, calculation errors, and administrative matters) were not
considered.
We deemed a problem to be signiﬁcant if the issue was
serious enough to prevent the PBAC from making a recommen-
dation for the medicine in accordance with the request in the
submission at the time. The reason(s) why the PBAC made a
decision to recommend (or not recommend) the listing of a
medicine is documented in the associated PSD. This does not
suggest that there were no signiﬁcant problems with submissions
for medicines that were recommended.
We felt that it was important to distinguish between “signiﬁ-
cant problems” and “uncertainty.” Submissions will always be
associated with uncertainty, even those that are recommended.
We sought to identify situations in which the level of uncertainty
in submissions was so great that it presented a signiﬁcant
problem to the PBAC.
The secrecy provisions of the National Health Act bind the
PBAC and submissions are treated as “commercial in conﬁdence.”
The signing of the Australia-United States Free Trade Agreement
in early 2005 facilitated the release of further information
regarding the basis for PBAC’s determinations regarding the
subsidy of medicines on the PBS in PSDs from mid-2005 [2].
PSDs are available only for submissions related to PBAC
considerations on the listing of medicines; they are not available
for other submissions for PBAC considerations, such as those
relating to pricing arrangements for listed medicines. We
included all published PSDs associated with submissions (initial
submissions and resubmissions) for medicines and vaccines
seeking a listing on the PBS. We excluded submissions with PSDs
for the following: Vaccines seeking a listing on the National Immunisation
Program [5]. Fixed-dose combination products seeking a listing on the PBS.
 Medicines seeking a listing on the Life Saving Drugs Program [6].
 Medicinal preparations (e.g., nutritional supplements) or devi-
ces seeking a listing on the PBS.
 New strengths or formulations of medicines already listed on
the PBS.
 Nonprescription medicines seeking a listing on the PBS.
 Medicines seeking a change to an existing therapeutic rela-
tivity to another listed medicine.
 Medicines for which the applicant was not the medicine’s
sponsor.
The largest proportions of the submissions we excluded were
for ﬁxed-dose combination products, National Immunisation
Program vaccines, and Life Saving Drugs Program medicines.
Insofar as the (current) PBAC guidelines consider ﬁxed-dose
combination products and National Immunisation Program vac-
cines as separate product types, they are subject to different
evidence requirements and hence their exclusion from the
analysis is justiﬁed. The exclusion of submissions for Life Saving
Drugs Program medicines is justiﬁed insofar as they are also
subject to additional decision-making criteria.6We sought to identify the types of problems in submissions as
used by Hill et al. [3] that had been ﬁrst described by O’Brien [7]
and are summarized in Table 1.
Hill et al. found that problems with the supporting clinical
evidence were the most common of all problem categories, but
they did not conduct further analysis to obtain deeper insights.
We developed additional frameworks in an attempt to under-
stand these problems at their core (Tables 2 and 3).
One of us (M.J.W.) developed a coding template. We coded
each eligible PSD using the template independently; differences
in opinion were resolved by consensus.
Some PSDs were for submissions with multiple requests that
were associated with different target patient populations (e.g.,
treatment-naive and treatment- experienced patients), different
proposed main comparators, and different clinical claims. In
these situations, we examined each request for each patient
population because there might have been a signiﬁcant problem
with one request but not the other.
Some submissions were associated with requests in the form
of options. We examined all options because there may have
been signiﬁcant problems in those that were not accepted by
the PBAC.
Determinations for all problem categories were made on the
basis of the clinical evidence presented in the submission. In
situations in which the submission did not include any clinical
data for PBAC’s preferred main comparator, a determination on
the estimate of comparative clinical efﬁcacy could not be made.Results
The PBAC published 598 PSDs for submissions considered
between July 2005 and November 2012; we excluded 119 (20%)
submissions, resulting in a study sample of 479 (80%) submis-
sions (Fig. 1).
Some submissions were excluded for more than one reason.
We identiﬁed 261 signiﬁcant problems in the 479 submissions, an
average of 0.54 signiﬁcant problems per submission (Table 4). The
479 submissions were associated with 483 PBAC outcomes.
Eighty-two percent of the submissions with a signiﬁcant problem
were associated with a rejection by the PBAC. Some submissions
were recommended despite having one or more problems with
the supporting clinical evidence. Invariably, they were recom-
mended on a different clinical and economic basis than proposed
by the sponsor. Submissions with no major problems with the
supporting clinical data might have been rejected by the PBAC for
another reason, such as uncertain or unacceptable cost-
effectiveness.
There was a signiﬁcant problem with the sponsor’s choice of
comparator in 11% of the submissions. There was no clear
temporal pattern, with at least one problem occurring at all bar
two PBAC meetings.
Randomized clinical trial evidence was not available for 4% of
the submissions. The most common signiﬁcant problem (140 or
29% of all submissions) was the determination of the medicine’s
comparative performance in the target patient population. Some
submissions had multiple problems insofar as they contained
multiple comparisons with different clinical claims (i.e., a claim
of clinical superiority vs. comparator A and a claim of clinical
noninferiority vs. comparator B).
There were a few examples in which the initial submission
did not clearly identify the target patient population for the
proposed medicine, and it took one to two resubmissions to
resolve this problem.
Most of the problems related to the medicine’s comparative
performance with respect to efﬁcacy, with only a few examples
Table 1 – Categorization of the signiﬁcant problems with the clinical evidence in major submissions to the PBAC.
Problem area Speciﬁc
problem
PBAC’s position Detail of problem Coding issues and challenges
Choice of
comparator
Choice of main
comparator
The main comparator is deﬁned as the
therapy that prescribers would most
replace with the proposed drug in
practice if the PBS subsidizes the
proposed drug as requested. In
practice, however, the main
comparator can be difﬁcult to identify.
The PBAC was of the view that
the proposed main
comparator in the submission
was inappropriate or that
additional comparisons were
required.
A submission was deemed to have a signiﬁcant
problem if the PBAC had a concern about the
sponsor’s choice of the main or secondary
comparator(s) to a sufﬁcient level that the
submission was rejected on that basis.
If the submission did not include any clinical
evidence on the PBAC’s preferred comparator,
then it was not possible for us to make
assessments on other aspects in the framework
Estimate of
comparative
clinical efﬁcacy
Availability of
randomized trial
evidence
The PBAC has a strong preference for
clinical and economic evaluations that
are based on direct randomized trials;
i.e., trials that directly compare the
proposed drug with the main
comparator.
The PBAC has considered and
will continue to consider all
levels of evidence. However,
the PBAC will be most
inﬂuenced by the results of
direct randomized trials as the
most rigorous source of data.
The supporting clinical evidence in submissions
ranged from case reports/case series to meta-
analyses of multiple randomized trials. For
some trials, we needed to use PubMed to
determine whether treatment allocation was
conducted in a randomized manner.
A submission was classiﬁed as having a
signiﬁcant problem if there was no supporting
randomized clinical trial evidence, irrespective
of whether or not the trial was a direct one
Poor-quality
evidence
The purpose of assessments of
measures to minimize bias is to
provide the sponsor and the PBAC with
a clear idea of which trials are of
greater scientiﬁc rigor. There is no
minimum standard, but the PBAC is
most likely to be persuaded by the data
of the highest scientiﬁc rigor.
The PBAC has developed a
quality checklist for the
assessment of the quality of
the randomized trial evidence.
The checklist covers
randomization, blinding, and
follow-up.
There are many aspects to poor-quality clinical
evidence. The deﬁnition of poor-quality clinical
evidence used by Hill et al. [3] is not clearly
stated in their article. To avoid double counting,
we did not consider problems associated with
treatment allocation. Insofar as poor-quality
clinical evidence presents a major challenge in
the determination of an estimate of
comparative clinical efﬁcacy, we were mindful
of further double counting. We considered a
submission to have a signiﬁcant problem if the
PBAC made an explicit statement in section 12
of the submission’s PSD on the poor quality of
the supporting clinical evidence. We recognize
that our count for problems in this category
may be lower than otherwise expected
Use of surrogate
outcome
The direct randomized trials might
report only those outcomes that are of
less patient relevance than intended
ﬁnal outcomes of treatment. These less
relevant outcomes are known as
surrogate outcomes. Arguably, the closer
a surrogate outcome is to the ﬁnal
outcome, the more useful it is, but
To transform the surrogate
outcomes measured in the
trials to ﬁnal outcomes and to
extend the range of outcomes,
the trial results might need to
be supplemented by estimates
obtained from other sources
Insofar as the use of a problematic surrogate
outcome in a submission would have presented
a challenge to the PBAC regarding the
determination of the magnitude of the clinical
beneﬁt of the proposed treatment in the target
patient population on ﬁnal outcome, there is a
risk of double counting.
Because the PBAC has not published a list of
acceptable surrogate outcomes for use in PBAC
continued on next page
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Table 1 – continued
Problem area Speciﬁc
problem
PBAC’s position Detail of problem Coding issues and challenges
generally the more difﬁcult it is to
measure accurately.
submissions, we chose not to code the
submissions on this category.
Analysis of
interpretation of
clinical evidence
The interpretation of the clinical data
presented in a submission is crucial in
determining its success. The PBAC has
developed a framework for the
classiﬁcation of the therapeutic
relativity of the proposed medicine
over its main comparator.
The essential difference
between assessing whether
the proposed medicine is
superior to the main
comparator is that the 95%
conﬁdence interval for
superiority excludes the
possibility that there is no
difference between the two
treatments.
This category relates to submissions for which a
claim of clinical superiority was made and
goes to the quality, strength, and relevance of
the supporting clinical evidence. There is
some overlap with poor-quality evidence.
Although many submissions had clinical
problems, some of them did not relate to the
supporting clinical evidence (i.e., the PBAC was
uncertain about the clinical need for the
medicine or the PBAC had some concerns about
the feasibility of the proposed restrictions).
These nonclinical evidence issues were not
considered to be “signiﬁcant problems”
Determination of
therapeutic
noninferiority
The interpretation of the clinical data
presented in a submission is crucial in
determining its success. The PBAC has
developed a framework for the
classiﬁcation of the therapeutic
relativity of the proposed medicine
over its main comparator.
The essential difference
between assessing whether
the proposed medicine is
noninferior to the main
comparator is that the 95%
conﬁdence interval for
noninferiority excludes the
possibility that the proposed
medicine is inferior to a
clinically important extent.
This category relates to submissions for which a
clinical claim of at least noninferiority was
made. Here, a submission was deemed to have
a signiﬁcant problem if
 The PBAC was satisﬁed that the proposed
medicine is noninferior to the comparator(s)
but at a different therapeutic relativity to that
proposed in the submission and the
submission was recommended on this basis
(data interpretation issue).
 The PBAC was not satisﬁed that the proposed
medicine is noninferior to the proposed
comparator(s) because of a wide noninferiority
margin and the submission was rejected on
that basis (data quality issue).
 The PBAC was not satisﬁed that the proposed
medicine is noninferior to the comparator(s)
and the submission was rejected or deferred on
this basis (data interpretation issue).
 The PBAC was satisﬁed that the proposed
medicine is actually inferior to the comparator
(s) and the submission was recommended on
that basis (i.e., less effective but also less costly)
(data interpretation issue).
 The PBAC wanted to obtain further
clinical advice.
PBAC, Pharmaceutical Beneﬁts Advisory Committee; PBS, Pharmaceutical Beneﬁts Scheme; PSD, public summary document.
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Table 2 – Categorization of the signiﬁcant problems with submissions to the PBAC that included a claim of clinical superiority.
Scenario Proposed
comparator
Target
patient
population
Proposed
outcome
Treatment
effect size
Clinical
signiﬁcance
Clinical
evidence issue
Justiﬁcation PBAC outcome Problem
category
A Accepted Unclear
(no
evidence)
NA NA NA The clinical
evidence in the
submission does
not encompass
the target
patient
population
The PBAC made the
comment in the PSD
that the target patient
population was not
identiﬁed in the
submission and a
resubmission was
subsequently prepared
and lodged with
different clinical
evidence base or a
resubmission could not
be prepared and lodged
as the requisite data do
not exist.
Rejection Data
relevance
B Accepted Unclear
(evidence
not
identiﬁed)
NA NA NA The target
patient
population is an
unidentiﬁed and
unanalyzed
subgroup of the
patient
population of
the clinical
evidence
The PBAC made the
comment in the PSD
that the target patient
population had not been
identiﬁed in the
submission. A
resubmission was
subsequently prepared
and lodged with the
same clinical evidence
base but with the target
patient population being
a clearly speciﬁed
subgroup of the patient
population of the initial
submission.
Rejection Data
relevance
C Accepted Clear Not
accepted
NA NA Relationship of
the proposed
outcome to a
patient-relevant
ﬁnal outcome
not established
in a quantitative
and/or
quantitative
manner
The PBAC made the
comment in the PSD
that the proposed
clinical outcome is
unacceptable or the
proposed outcome is
acceptable but the
submission contained
insufﬁcient evidence to
support the proposition
that the outcome is
related to a patient-
Rejection Data quality
continued on next page
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Table 2 – continued
Scenario Proposed
comparator
Target
patient
population
Proposed
outcome
Treatment
effect size
Clinical
signiﬁcance
Clinical
evidence issue
Justiﬁcation PBAC outcome Problem
category
relevant ﬁnal outcome
or another patient-
relevant outcome.
D Accepted Clear Accepted Unclear NA Trial design and
conduct
shortcomings
The PBAC made the
comment in the PSD
that the proposed
outcome is acceptable
and that its relationship
to a patient-relevant
ﬁnal outcome is
sufﬁciently well
established but the
magnitude of the
treatment effect on a
patient- relevant ﬁnal
outcome is unclear.
Rejection Data quality
E Accepted Clear Accepted Accepted Unclear/not
established
Minimal
clinically
important
difference not
established
The PBAC made the
comment in the PSD
that the proposed
outcome is acceptable
and that the magnitude
of the treatment effect
on a patient-relevant
outcome is clear but the
clinical signiﬁcance of
the treatment effect size
is uncertain.
Recommendation,
rejection, or
deferral
Data
interpretation
F Accepted Clear Accepted Unclear Unclear The PBAC
disputed the
claimed clinical
beneﬁt
The PBAC made the
comment in the PSD
that the clinical claim is
unreasonable and that a
different clinical claim
is appropriate.
Recommendation,
rejection, or
deferral
Data
interpretation
NA, not applicable; PBAC, Pharmaceutical Beneﬁts Advisory Committee; PSD, public summary document.
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Table 3 – Categorization of the signiﬁcant problems with submissions to the PBAC that included a claim of
clinical noninferiority.
Scenario Claim of
therapeutic
noninferiority
Clinical evidence issue Justiﬁcation PBAC outcome Problem
category
M Not accepted The PBAC was unable to
determine whether the
medicine is noninferior or
inferior to comparator with
respect to efﬁcacy and/or
safety.
The PBAC made the
comment in the PSD that the
clinical claim in the
submission was
unreasonable and that it was
unable to determine what
clinical claim could be made.
Rejection Data quality
N Not accepted The PBAC was satisﬁed that
the clinical evidence in the
submission supports a claim
of inferiority (efﬁcacy) or a
different position (safety)
The PBAC made the
comment in the PSD that a
different clinical claim was
reasonable.
Recommendation
(different basis)
Data
interpretation
O Not accepted Noninferiority (efﬁcacy)
margin has not been
established or was not
speciﬁed in the clinical trial.
The PBAC made the
comment in the PSD that the
noninferiority margin was
unacceptably wide.
Rejection Data quality
P Not accepted The PBAC was satisﬁed that
the clinical evidence in the
submission supports a
different therapeutic
relativity to that proposed by
the sponsor.
The PBAC made the
comment in the PSD that the
proposed therapeutic
relativity was unreasonable
and that a different
therapeutic relativity was
appropriate.
Recommendation
(different
therapeutic
relativity)
Data
interpretation
Q Not accepted The PBAC was not clear
about the clinical positioning
of the medicine or was
uncertain that the clinical
evidence supported the
clinical claim.
The PBAC made the
comment in the PSD that it
wanted to obtain further
clinical advice.
Deferral or
rejection
Data
interpretation
PBAC, Pharmaceutical Beneﬁts Advisory Committee; PSD, public summary document.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 6 7 – 4 7 6 473related to a comparative safety claim (e.g., a claim of a lower
incidence of hypoglycemic events).
A common scenario was that the PBAC did not accept the
claim of clinical superiority over the comparator because of
uncertainty over the magnitude of the incremental treatment
effect on a ﬁnal outcome.
Matters of interpretation such as the determination of the
clinical relevance of the difference of the proposed medicine over
its comparator on an acceptable outcome were often resolved
with further discussion and resubmission(s) without the need for
substantive new clinical evidence. These submissions often had
pricing implications.
The determination of clinical noninferiority was a problem in
34 (7%) submissions; all related to a claim of noninferiority that
was inadequately supported or justiﬁed. In some cases, the
submission was rejected, whereas in others the submission was
recommended on the basis of a different therapeutic relativity. In
three cases, the medicine was recommended on the basis of a
different clinical claim (i.e., clinical inferiority) (Table 5).Discussion
The supporting clinical evidence is the foundation of a robust and
credible PBAC submission. We found a rather poor ﬁt for purpose;
in recent times, on average, one in every two major submissions
to the PBAC had a signiﬁcant problem with the supportingclinical evidence. A problem with the choice of comparator
occurred, on average, with 1 in every 10 major submissions.
The absence of randomized controlled trial (RCT) evidence in
a submission was not a frequent occurrence (4% of all submis-
sions) and was seldom a reason for its rejection. In our view, the
absence of RCT evidence in a submission is not a signiﬁcant
problem. We share the concern of past National Institute for
Health and Care Excellence Chairman Sir Michael Rawlins about
RCTs being considered by some to be the “gold standard” of
clinical evidence. Although RCTs are very important, evidence
from other study designs “can be appropriate in some circum-
stances” [8].
There are many aspects to poor-quality clinical evidence (e.g.,
inadequate blinding, suboptimal dose of comparator, early cross-
over, inadequate wash-out period, high discontinuation rate, and
short period of observation). We could ﬁnd an explicit mention in
the PSDs of the supporting clinical evidence being of poor quality
in only 15 (3%) submissions; this ﬁgure seems artiﬁcially low
given that there were 68 submissions for orphan drugs. We chose
not to consider the use of surrogate outcome as a problem
because the use of a surrogate outcome in a submission is in
itself not a reason for its rejection and the PBAC is yet to publish a
list of acceptable (or unacceptable) surrogate outcomes. None-
theless, our research shows that the use of a surrogate outcome
in a submission did not always pose a signiﬁcant problem to
the PBAC.
We developed an additional evaluation framework to inves-
tigate the apparent shortcomings of the supporting clinical
PSDs for submissions (n = 598)
PSDs for included major submissions (n = 479)
Major
submissions for
orphan drugs
(n = 69)
Major submissions for
nonorphan drugs (n = 410)
PSDs for excluded submissions (n = 119)
Submissions for fixed
combination products (n = 42)
Submissions for NIP vaccines
(n = 21)
Submissions for LSDP medicines
(n = 19)
Minor submissions (n = 14)
Submissions for new strengths or
formulations (n = 9)
Submissions for nonprescription
medicines (n = 7)
Submissions for medicinal
preparations (n = 1)
Nonindustry submissions (n = 1)
Therapeutic relativity (n = 1)
Fig. 1 – Included and excluded submissions. LSDP, Life Saving Drugs Program; NIP, National Immunisation Program; PSD,
public summary document.
Table 4 – Categorization of the types of signiﬁcant
problems identiﬁed in submissions to the PBAC
(July 2005–November 2012).
Problem area Speciﬁc problem No. (%) of
all problems
Choice of
comparator
Choice of main
comparator
53 (20)
Estimate of
comparative
clinical efﬁcacy
Availability of
randomized clinical
trial evidence
18 (7)
Poor-quality evidence 16 (6)
Analysis of
interpretation of
clinical evidence
140 (54)
Determination of
therapeutic
noninferiority
34 (13)
PBAC, Pharmaceutical Beneﬁts Advisory Committee.
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was relevant to the reimbursement decision-making question.
The results clearly show that the most frequent problem category
was the inadequacy of the clinical evidence in being able to
support a claim of clinical superiority and/or clinical noninfer-
iority. In the case of the former, it shows that the PBAC often had
to grapple with a claim of clinical superiority on a patient-
relevant ﬁnal outcome based on a favorable change in an accept-
able surrogate outcome. In the case of the latter, it shows that
submissions that included a seemingly safer claim of clinical
noninferiority were not without their problems, with the PBAC
being unsure as to whether a claim of clinical inferiority might be
the correct conclusion.
Our study has a number of limitations. We identiﬁed a small
number of major submissions with no associated PSD. Their
exclusion is unlikely to have a bearing on our results. We
excluded 107 (18%) submissions for various reasons (Fig. 1). The
content of a given PSD is negotiated between the PBAC and the
medicine’s sponsor, so it is possible that information on some
problems has not been published. Any omitted problems are
likely to have been minor ones that did not have a major
inﬂuence on a submission’s outcome.
Table 5 – Submissions with signiﬁcant problems with the associated claim of clinical superiority or
noninferiority.
Submission
claim
Problem
category
Description No. (%) of all
problems
Clinical
superiority
A (Data
relevance)
No clinical data for target patient population 5 (4)
B (Data relevance) Clinical data for target patient population inadequately identiﬁed 10 (7)
C (Data quality) Proposed surrogate outcome not accepted 10 (7)
D (Data quality) Treatment effect on ﬁnal outcome not clear 85 (61)
E (Data
interpretation)
Clinical signiﬁcance of treatment effect on ﬁnal outcome in dispute 6 (4)
F (Data
interpretation)
The PBAC is of the view that a different clinical claim is more
appropriate
24 (17)
Clinical
noninferiority
M (Data quality) The PBAC was unable to determine a therapeutic relativity 26 (76)
N (Data
interpretation)
The PBAC was of the view that a different clinical claim was more
appropriate
3 (9)
O (Data quality) The PBAC had concerns about the noninferiority margin 1 (3)
P (Data
interpretation)
The PBAC was of the view that a different therapeutic relativity was
more appropriate
2 (6)
Q (Data
interpretation)
The PBAC wanted to obtain further clinical advice 2 (6)
PBAC, Pharmaceutical Beneﬁts Advisory Committee.
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reported on their review of 326 major submissions to the PBAC
from 1994 to 1997. They identiﬁed many signiﬁcant problems; of a
total of 326 submissions, 218 had serious problems of interpre-
tation and were included in their analysis. Signiﬁcant problems
were those considered to have a signiﬁcant bearing on the
decision making of the PBAC and were classiﬁed as comparator
issues, comparative clinical efﬁcacy issues, modeling issues, and
calculation errors. This result was not surprising given that few
governments were using HTA methods to inform their decision
making. Therefore, the pharmaceutical industry had little need to
generate the sort of clinical data needed by HTA agencies.
Like Hill et al, we found a large numbers of problems with the
clinical evidence in submissions to the PBAC. The overall rate of
signiﬁcant problems in major submissions to the PBAC does not
appear to have changed since the mid-1990s. We observed more
problems with the analysis of the interpretation of the clinical
evidence and fewer problems with the determination of ther-
apeutic noninferiority than did Hill et al. This could be explained
by a higher proportion of submissions for medicines with a claim
of clinical superiority in our study. Because Hill et al. did not
present any data to enable such a comparison, we are unable to
determine this.
The ﬁndings from our study have international implications
because it is likely that HTA agencies in other countries such as
the National Institute for Health and Care Excellence have
encountered similar types of problems in their assessment of
the available clinical evidence for reimbursement/coverage deter-
minations. A common denominator of the different publicly and
privately funded health care technology reimbursement systems
is the strength and relevance of comparative “clinical evidence.”
This holds true irrespective of whether or not the agencies
require the evidence to be presented to them in submissions
from the developers of the medicines concerned because the
issue is more about the underlying clinical evidence rather than
the failure of the developers to identify and then present it.
We are not aware of similar research being conducted in other
jurisdictions, so we cannot determine whether our ﬁndings of the
clinical evidence being a poor ﬁt for purpose are conﬁned to
Australia. We note the recent studies by Kaltenthaler et al. [9,10]
on the identiﬁcation of issues associated with the ﬁrst 95 singletechnology assessments undertaken by the National Institute for
Health and Care Excellence and a review of the evidence to
inform the population of cost-effectiveness models within HTAs.
In neither study did they undertake an assessment of the quality
of the supporting clinical evidence.
Problems with the choice of comparator are not unique to the
PBAC; they have occurred with submissions to HTA agencies in
other jurisdictions such as the Institute for Quality and Efﬁciency
in Health Care in Germany and the Canadian Drug Expert
Committee in Canada [11–13]. It is unclear as to whether choice
of comparator issues are more or less common in Australia.
In the absence of empirical evidence on the quality of clinical
evidence considered by other HTA agencies, the extent of prob-
lems in other jurisdictions is unknown.
The evaluation framework we developed could be used to
conduct such research that could be performed by “independent”
researchers if there is considerable information on the assess-
ments and determinations in the public domain. Should such
research be conducted and derive similar ﬁndings to ours, it will
raise important issues regarding what can and should be done by
all stakeholders to improve the quality of the clinical evidence
used to support the reimbursement/coverage of new medicines.Acknowledgments
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